Company profile
COGNITION THERAPEUTICS INC
NASDAQ:CGTXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zervimesine | phase2 | — | 9 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05531656 | phase2 | active_not_recruiting | 2023-06-28 | 2027-05-31 | Cognition Therapeutics | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease |
| NCT03507790 | phase2 | completed | 2018-10-10 | 2024-05-29 | Cognition Therapeutics | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. |
| NCT02570997 | phase1 | completed | 2015-09-01 | 2016-05-01 | Cognition Therapeutics | Ascending Dose Study of CT1812 in Healthy Volunteers |
| NCT02907567 | phase1_2 | completed | 2016-09-01 | 2017-08-24 | Cognition Therapeutics | Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease |
| NCT03716427 | phase1 | completed | 2016-11-10 | 2016-12-27 | Cognition Therapeutics | Drug Interaction Study of CT1812 in Healthy Volunteers |
FDA applications (0)
No records yet.